Immunotherapy is a breakthrough in different tumor entities. Recently, immunotherapy became an important treatment modality in gastrointestinal (GI) malignancies. In GI malignancies, immunotherapy with or without chemotherapy or targeted agents is …

Numerous kinases act as central nodes of cellular signaling networks. As such, many of these enzymes function as molecular switches for coordinating spatiotemporal signal transmission. Typically, it is the compartmentalized phosphorylation of …

SCLS is a rare and fatal angiopathy characterized by reversable protein leakage into the interstitial space leading to a classical triad of hypotension, hypoalbuminemia and hemoconcentration [ 1 ]. The exact incidence of SCLS is unknow since this …

Agents targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) are part of systemic therapy in advanced colorectal cancer. It is well known that only certain molecular subpopulations profit from EGFR …

Palliative care has evolved over the past five decades as an interprofessional specialty to improve quality of life and quality of care for patients with cancer and their families. The main objective in an end-of-life (EOL) situation is to …

Antibody–drug conjugates (ADCs) against numerous molecular targets are currently being developed for the treatment of breast cancer (BCa). While the first ADC directed against Her2, namely trastuzumab–emtansine, was approved several years ago …

For patients suffering from localized and advanced stage esophageal cancer, long-term outcomes remain poor. However, as already seen in other tumors, the introduction of immune checkpoint inhibitors has led to practice-changing results in the …

In recent years, treatment of patients exhibiting chronic lymphocytic leukemia has changed extensively due to advances in the development of targeted therapies. The Bcl‑2 inhibitor venetoclax demonstrated outstanding results when used in mono- as …

New agents and combinations continue to change the clinical practice of treating patients with renal cell carcinoma. In this review we want to highlight the most recent therapeutic developments and also give an overview of the current standard of …

Chronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Currently, patients are mostly treated with so-called novel agents, including Bruton tyrosin kinase (BTK) inhibitors and BCL‑2 …

Coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO) on 11 March 2020 [ 1 ]. Patients with comorbidities such as hypertension (HT), cardiovascular disease, diabetes mellitus (DM), chronic …

Given the growing use of immune checkpoint inhibitor (ICI) therapy in oncology, the prevalence of endocrine side effects is rapidly increasing. As clinicians are nowadays frequently confronted with these side effects in routine clinical care …

Multiple myeloma (MM) is a malignant B‑cell disorder characterized by heterogeneous cytogenetic abnormalities, resulting in a wide heterogeneity in survival outcomes [ 1 , 2 ]. Although treatment strategies for MM have improved in the last decade …

Tremendous advances in modern oncology therapies enable an increasing life expectancy of many cancer entities. Short or long-term cardiovascular side effects, however, gain importance. The current review focuses on recent recommendations for …

We report the case of a 64-year-old man with CML in the chronic phase that was originally diagnosed in 2014. His past investigations at the time of diagnosis of CML in the chronic phase revealed the following: baseline CBC-Hb 9.9 g/dl, TLC …

Recent innovative advances, especially concerning immunotherapeutic agents and targeted therapies, have changed the face of modern oncology. The year 2020 represents a milestone in the treatment of gastroesophageal cancer because several trials …

Immune checkpoint blockade (ICB) has fundamentally improved the treatment landscape of advanced lung cancer. Improved tolerability and encouraging duration of response in selected patients are some of the advantages of ICB over conventional …

The treatment landscape of chronic lymphocytic leukemia (CLL) has shifted from chemotherapy-based approaches to targeted agents in the last decade. However, evolving drug resistance and accumulating toxicity remain challenges that still limit …

We present a case of a male patient with advanced hepatocellular carcinoma who developed hepatic and dermatological immune-related adverse events during treatment with the immune checkpoint inhibitor nivolumab. We discuss relevant aspects …

Neoadjuvant therapy is well-accepted in the treatment of borderline resectable and locally advanced PC, the benefit of neoadjuvant chemotherapy in patients with resectable disease, however, is currently not so clear. Here we provide an up date on …